Skip to main content
main-content

Lung cancer

Lung cancer

26-10-2021 | Oncology | News | Article

ICIs linked to increased venous thromboembolism risk

A large single-center study has found an association between immune checkpoint inhibitor use and an increased incidence of venous thromboembolism in people with cancer.

25-10-2021 | Oncology | News | Article

Chemotherapy-related toxic effects reduced with geriatric assessment-driven intervention

A geriatric assessment-driven intervention may reduce the risk for grade 3 or higher chemotherapy-related toxicities in older people with cancer, research suggests.

20-10-2021 | Oncology | News | Article

Adjuvant atezolizumab approved by FDA for NSCLC patients

For more information on the approval, click here

18-10-2021 | Oncology | News | Article

Amivantamab receives EMA support for EGFR exon 20-mutated NSCLC

Click through to read more on this positive opinion

14-10-2021 | Oncology | News | Article

Cancer surgery systems need strengthening against future societal lockdowns

Data form the international COVIDSurg collaborative study show that around one in seven patients did not undergo planned surgery for cancer if their region was in full COVID-19 lockdown.

12-10-2021 | Oncology | News | Article

Thoracic ultrasonography may lead to shorter pleurodesis hospital stays

Using thoracic ultrasonography to guide pleurodesis leads to shorter hospital stays, with similar success rates, compared with standard care in people with malignant pleural effusion, SIMPLE study findings indicate.

06-10-2021 | Oncology | News | Article

CT analysis helps define COVID-19 vaccine-related axillary lymphadenopathy

An analysis of computed tomography scans from people with thoracic malignancies shows that approximately one in 11 people develop axillary lymphadenopathy following mRNA-based COVID-19 vaccination.

05-10-2021 | Oncology | News | Article

TP53, KEAP1 mutations could be biomarkers for NSCLC survival

Truncating TP53 mutations are associated with shorter survival in people with localized non-small-cell lung cancer while mutations in KEAP1 are linked to poor outcomes in both localized and advanced disease, German researchers report.

30-09-2021 | Oncology | News | Article

Pralsetinib receives nod from EMA for use in RET-positive NSCLC

Click through to read more details

22-09-2021 | Oncology | News | Article

CASPIAN update cements durvalumab–chemo as standard of care for extensive-stage SCLC

The overall survival advantage offered by the use of durvalumab alongside first-line chemotherapy in people with extensive-stage small-cell lung cancer is sustained over time, suggests the 3-year follow-up of the CASPIAN study.

19-09-2021 | Oncology | News | Article

Trastuzumab deruxtecan supported for pretreated HER2-mutant NSCLC

Trastuzumab deruxtecan achieves durable responses in individuals who have received prior treatment for metastatic non-small-cell lung cancer harboring HER2 mutations, suggests the DESTINY-Lung01 trial.

18-09-2021 | Oncology | News | Article

COAST points to potential of durvalumab combinations in stage III NSCLC

Individuals with unresectable locally advanced non-small-cell lung cancer and no progression after chemoradiotherapy could benefit from the addition of the CD73 inhibitor oleclumab or the NKG2A-targeted agent monalizumab to consolidation durvalumab, suggest phase 2 results.

17-09-2021 | Oncology | News | Article

FDA approves mobocertinib for advanced NSCLC with EGFR exon 20 insertions

Click through to read more about this approval

15-09-2021 | Oncology | News | Article

No overall survival benefit with first-line bevacizumab–erlotinib in EGFR-mutant NSCLC

The addition of bevacizumab to erlotinib does not improve the overall survival of treatment-naïve patients with advanced non-small-cell lung cancer harboring an activating EGFR mutation, NEJ026 study data show.

14-09-2021 | Oncology | News | Article

Flexibility positively impacts lung cancer clinical trial participation in COVID-19 era

Strategies to improve flexibility in clinical trials may improve enrollment rates during and after the COVID-19 pandemic, according to a study presented at the IASLC 2021 World Conference on Lung Cancer.

13-09-2021 | Oncology | News | Article

​​​​​​​Pretreatment ctDNA levels may predict survival in neoadjuvant-treated NSCLC patients

Assessing circulating tumor DNA levels prior to initiating neoadjuvant chemoimmunotherapy for locally advanced non-small-cell lung cancer could help to identify patients likely to derive long-term benefit from treatment, suggest exploratory data.

13-09-2021 | Oncology | News | Article

Atezolizumab plus chemotherapy feasible for NSCLC with brain metastases

Treatment with carboplatin and pemetrexed plus atezolizumab shows promise for people with nonsquamous non-small-cell lung cancer and asymptomatic, untreated brain metastases, phase 2 study findings indicate.

10-09-2021 | Oncology | News | Article

No OS benefit of lurbinectedin plus doxorubicin in relapsed SCLC

The ATLANTIS trial has found no significant overall survival improvement with the combination of lurbinectedin and doxorubicin versus chemotherapy in previously treated patients with small-cell lung cancer.

09-09-2021 | Oncology | News | Article

Durvalumab–tremelimumab plus chemo ‘a potential new first-line option’ for metastatic NSCLC

The addition of durvalumab plus tremelimumab to chemotherapy significantly improves the outcomes of people with untreated metastatic non-small-cell lung cancer, shows the POSEIDON trial.

07-09-2021 | Oncology | News | Article

Single-fraction SABR may be preferred for lung oligometastases

Stereotactic ablative body radiotherapy offers similar outcomes, in terms of toxicity and efficacy, whether it is given as a single fraction or in multiple fractions to patients with up to three lung oligometastases, SAFRON II trial data show.

Image Credits